NDATOPICALSUSPENSION
Approved
May 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
5/8 — Partial
TACLONEX (calcipotriene and betamethasone dipropionate) by Leo Pharma is 3 analog and betamethasone dipropionate as a synthetic corticosteroid. Approved for plaque psoriasis. First approved in 2008.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TACLONEX is a topical suspension combining calcipotriene (a vitamin D3 analog) and betamethasone dipropionate (a synthetic corticosteroid) for treating plaque psoriasis of the scalp and body, as well as nail psoriasis. The exact mechanism of action in psoriasis remains incompletely understood, though both components are known to have anti-inflammatory and immunomodulatory effects. It is administered as a topical suspension.
$0.665MPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending ($665K in 2023), this product faces significant commercial headwinds and likely operates as a smaller, declining team focused on managing existing patient base through generic transition.
Mechanism of Action
3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis of the scalp and body are unknown.
Indications (1)
Clinical Trials (6)
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
Started Jul 2013
147 enrolled
Psoriasis Vulgaris
A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
Started Jan 2013
8 enrolled
Psoriasis
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
Started Oct 2012
20 enrolled
Plaque Psoriasis
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Started Jul 2009
33 enrolled
Psoriasis Vulgaris
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
Started Jan 2008
6 enrolled
Plaque Psoriasis
Worked on TACLONEX at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.